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SYNOPSIS: 
The dexamethasone implant for adult patients with non-infectious posterior segment-involving uveitis 
is estimated to be cost-effective using generally accepted UK thresholds. However, there is substantial 
uncertainty around these results and further primary research is recommended.   
ABSTRACT  
Background 
Uveitis is inflammation inside the eye. The objective of this study is to assess the cost-effectiveness of 
a dexamethasone implant plus current practice (immunosuppressants and systemic corticosteroids) 
compared with current practice alone, in patients with non-infectious intermediate, posterior or pan- 
uveitis and to identify areas for future research.  
Methods 
A Markov model was built to estimate the costs and benefits of dexamethasone. Systematic reviews 
were performed to identify available relevant evidence. Quality of life data from the key randomised-
controlled trial (HURON) was used to estimate the LQWHUYHQWLRQV¶ effectiveness compared with the 
trial¶s comparator arm (placebo plus limited current practice (LCP)). The analysis took a National 
Health Service and Personal Social Services perspective. Costs were calculated based on standard UK 
sources.  
Results 
The incremental cost-effectiveness ratio (ICER) of one dexamethasone implant compared with LCP is 
estimated as £19,509 per quality-adjusted life year (QALY) gained. The factors with the largest 
impact upon the results were rate of blindness and relative proportion of blindness cases avoided by 
dexamethasone. Using plausible alternative assumptions, dexamethasone could be cost saving, or it 
may be associated with an ICER of £56,329 per QALY gained compared with LCP.  
Conclusions 
Dexamethasone is estimated to be cost-effective using generally accepted UK thresholds. However 
there is substantial uncertainty around these results due to scarcity of evidence. Future research on the 
following would help provide more reliable estimates: effectiveness of dexamethasone versus current 
practice (instead of LCP), with subgroup analyses for unilateral and bilateral uveitis; incidence of long 
term blindness; and effectiveness of dexamethasone in avoiding blindness. 
  
INTRODUCTION  
Uveitis is a group of conditions characterised by inflammation inside the eye. Complications of 
uveitis including cystoid macular oedema, vitreous haze, cataracts, glaucoma, and irreversible damage 
to the retina may lead to loss of vision. Uveitis generally presents in people of working age and 
accounts for 10% of cases of legal blindness, defined here as best-corrected visual acuity of 20/200 or 
less in the better-seeing eye and/or a visual field of 20 degrees or less.[1] 
Dexamethasone intravitreal implant (Ozurdex, Allergan) is a corticosteroid implant which suppresses 
inflammation by inhibiting the expression of pro-inflammatory mediators. Dexamethasone implant 
has a marketing authorisation from the European Medicines Agency (EMA) for treating adults with 
inflammation of the posterior segment of the eye presenting as non-infectious uveitis.[2] The 
prevalence of non-infectious posterior segment-involving uveitis is estimated to be between 3 and 10 
out of 100,000 people.[2]  
Non-infectious posterior segment-involving uveitis is usually treated with corticosteroids first line, 
which may be administered systemically or locally. Long-term use of systemic corticosteroids above 
7.5mg per day is not recommended due to the side effects which include cataract, glaucoma, diabetes, 
osteoporosis, weight gain and raised blood pressure. Second line treatment is typically 
immunosuppressive drugs including methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus 
and azathioprine, and these can allow a reduction in the corticosteroid dose and associated 
complications. It is expected that dexamethasone implant could provide an alternative second line 
option for patients who have unilateral uveitis or asymmetric bilateral uveitis, where systemic disease 
is not present or is well-controlled.   
However, national funding bodies need to know if dexamethasone implants are cost-effective in order 
to inform recommendations for clinical practice. To our knowledge, this is the first economic 
evaluation of the dexamethasone implant in patients with non-infectious uveitis. The objective of this 
study is to assess the cost-effectiveness of dexamethasone compared with current practice in England 
in patients with non-infectious intermediate, posterior or panuveitis and to identify areas for future 
research.  
 
METHODS 
A systematic review of existing economic evaluations was undertaken of the dexamethasone implant 
for non-infectious uveitis. Since no relevant economic evaluations were identified from the review, a 
de novo economic model was developed. Systematic reviews were also undertaken of the 
effectiveness evidence and utility estimates which have been described elsewhere.[3]  
Health Economic Model Scope 
The model population consists of adults with active non-infectious intermediate, posterior or pan 
uveitis, with a mixture of unilateral and bilateral uveitis.  
The comparator is current UK practice, which for the main analysis is assumed to be equivalent to the 
control arm of the main randomised controlled trial of the dexamethasone implant, HURON.[4] In 
this group, 25% of patients were using systemic immunosuppressants (such as methotrexate, 
mycophenolate mofetil, cyclosporine and azathioprine) or anti-inflammatory treatment at baseline and 
they were allowed rescue therapy with new corticosteroids or immunosuppressants. In current UK 
practice, a greater proportion of patients are likely to receive systemic immunosuppressants or anti-
inflammatory treatment than in the control arm of the HURON trial. As such the comparator for the 
main analysis is denoted throughout as limited current practice based on HURON (LCP(H)). An 
exploratory analysis was also undertaken to assess the impact of alternative baseline effectiveness, 
based on the comparator of the Multicentre Uveitis Steroid Treatment (MUST) trial.[5] A systematic 
review was undertaken which found no other evidence of the effectiveness of the dexamethasone 
implant from a randomised controlled trial. Observational studies of the implant have been reported 
and these are discussed later; however they do not provide evidence of the relative impact of 
dexamethasone. The intervention being assessed is one 0.7mg dexamethasone implant provided in 
one eye, plus LCP(H), to be consistent with the HURON trial.[4]  
The main outcome of the model is the incremental cost per quality-adjusted life year (QALY) gained 
for dexamethasone compared with current practice. QALYs are estimated by assigning a health-
related utility value to each health state in the model, where 0 is equivalent to death and 1 is 
HTXLYDOHQW WR IXOO KHDOWK DQG VXPPLQJ WKHVH RYHU WKH SDWLHQWV¶ OLIHWLPH The incremental cost per 
QALY gained is the difference in costs associated with the dexamethasone implant and current 
practice divided by the difference in QALYs associated with the dexamethasone implant and current 
practice. This outcome allows the cost-effectiveness of dexamethasone to be compared against other 
healthcare interventions for different populations and indications. The analysis is performed from a 
National Health Service (NHS) and Personal Social Services (PSS) perspective and costs and QALYs 
are discounted at a rate of 3.5% per year as recommended by the National Institute for Health and 
Care Excellence (NICE),[6] since this work was used to inform a decision about how to spend NHS 
and PSS resources.[7] An accompanying model of adalimumab for this population was also 
developed to inform the same NICE guidance, which is reported elsewhere.[8][9]   
 
Health Economic Model Design 
A Markov model was developed, which simulates a cohort of patients through a set of mutually 
exclusive health states, with probabilities of moving between the states every time cycle. Patients 
enter the model with a mean age of 44.8, based on HURON,[4] and are followed over a lifetime.  
 
There are four health states: (i) dexamethasone implant, no blindness; (ii) no dexamethasone implant, 
no blindness; (iii) blindness; and (iv) death, as shown in Figure 1. Patients in the dexamethasone 
implant group VWDUW LQ WKH ³GH[DPHWKDVRQH LPSODQW QR EOLQGQHVV´ VWDWH DQG PRYH WR WKH ³no 
dexamethasone implant effectQREOLQGQHVV´VWDWH after 30 weeks. Patients in the comparator group 
begin immediately in the ³QR GH[DPHWKDVRQH LPSODQW HIIHFW QR EOLQGQHVV´ state. Each 2-weekly 
cycle, patients have a probability of experiencing permanent damage to the eye, transitioning to 
³EOLQGQHVV´ 3DWLHQWV FDQ also WUDQVLWLRQ WR WKH ³GHDWK´ VWDWH. Treatment benefit is represented with 
higher health-related quality of life (HRQoL) and lower rates of condition-related adverse events 
ZKLOVW LQ WKH ³dexamethasone implant QR EOLQGQHVV´ VWDWH DV ZHOO DV a reduced risk of permanent 
blindness. The health states of the model were chosen to reflect the events which were thought to have 
the largest impact upon costs and quality of life. Searches were undertaken around the disease natural 
history of blindness for uveitis patients to inform the transitions between health states. 
 
Model inputs 
Model inputs were taken from a variety of sources. A summary of these parameters are included in 
Table 1. 
Table 1: Model input parameters for the base case analysis 
Parameters Mean Distribution 
used in PSA  
Source 
Starting age (active/inactive) 44.8 Fixed HURON [4] 
Discount rate (costs and utilities) 3.5% Fixed NICE Reference Case [6] 
Gender (% males) 36.7% Fixed HURON [4] 
Cycle length 2 weeks Fixed  
Utilities    
Baseline VFQ-25 for the 
dexamethasone implant and 
LCP(H) 
66.63 Beta HURON [4] 
Blindness utility 0.38 Multivariate 
normal  
Czoski-Murray et al. [10] 
Proportion of uveitis patients with 
bilateral disease in the UK 
75% Beta Expert clinical opinion 
Proportion of uveitis patients with 
bilateral disease in the HURON 
trial 
70% 
Beta 
Combination of patient level data 
from the HURON trial [4] and 
clinical opinion 
Probability of blindness (annual) 0.0068 Beta Dick et al. [11] 
Parameters Mean Distribution 
used in PSA  
Source 
Relative risk of blindness for 
dexamethasone versus no implant 
during 6 month period following 
implantation 
0.5 Uniform Assumption 
Drug costs    
Dexamethasone 0.7mg £870 Fixed BNF, 2016[12] 
Prednisolone £1.24 Fixed BNF [13] 
Mycophenolate mofetil £9.31 Fixed BNF [13] 
Methotrexate £2.40 Fixed BNF [13] 
Cyclosporine £48.50 Fixed BNF [13] 
Azathioprine £3.24 Fixed BNF [13] 
Bimatoprost £11.71 Fixed BNF [13] 
Adcal D3 £7.49 Fixed BNF [13] 
Omeprazole £1.17 Fixed BNF [13] 
Administration and monitoring  
Monitoring visit frequency 6 weeks  Jabs et al. [14] 
Monitoring visit cost £96.11 Gamma  NHS Reference costs 2014-
15[15] 
Dexamethasone implant 
administration cost 
£113.42 Gamma NHS Reference costs 2014-15, 
Minor Vitreous Retinal 
Procedures[15] 
Costs of adverse events    
Cataract surgery £852.40 Gamma NHS Reference costs 2014-15 
[15] 
Raised intraocular pressure £23.42 Gamma BNF [13] 
Glaucoma procedure £581.25 Gamma NHS Reference costs 2014-
15[15] 
Hypertension £7.04 Gamma Breeze et al. [16] 
Blindness (transition) £237 Gamma Colquitt et al. [17] 
Blindness (annual) £7,659 Gamma Colquitt et al. [17] 
Fracture £2,116.17-
£6,022.62 
Gamma Davis et al. [18] 
Diabetes £1,521.46 Gamma Alva et al. [19], Breeze et al. [16] 
 
Health-related quality of life 
The VFQ-25 health-related quality of life (HRQoL) outcome was used because it captured most fully 
the positive and negative effects of the implant. The use of visual acuity and vitreous haze outcomes 
within the model were also considered, however the VFQ-25 was preferred because of the difficulties 
associated with capturing all impacts of the dexamethasone implant using one visual outcome. The 
HURON trial [4] reports VFQ-25 health-related quality of life (HRQoL) data at baseline and at each 
follow-up visit.  
Another HRQoL measure that was collected at baseline within the trial was the five dimensional 
EuroQol (EQ-5D) measure, including mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. This is a standardised instrument which is considered to be the gold standard in 
order to compare HRQoL across a wide range of health conditions and treatments.  It is necessary to 
convert VFQ-25 data to EQ-5D utilities in order to estimate QALYs, as required by NICE in order to 
enable a comparison of the cost-effectiveness of all interventions across different patient populations. 
The manufacturer of the dexamethasone implant, Allergan, shared patient-level data from the 
HURON trial with the project team which allowed an analysis of the relationship between VFQ-25 
and EQ-5D using the baseline data.  
A linear regression model was fitted to the data from HURON to predict EQ-5D utilities from the 
VFQ-25, as shown in Figure 2, assuming that the relationship is independent of treatment: 
EQ-5D utility = 0.4454059 + VFQ-25 score*0.0051322 
Alternative non-linear models (eg. quadratic regression) were also tested but did not significantly 
improve the fit to the data.  
The utility for patients entering the model was set to be the same for both the dexamethasone implant 
group and the comparator by calculating the average VFQ-25 from these two arms of the HURON 
trial, and using the linear regression to predict the EQ-5D utility. Utility over time was estimated 
using the VFQ-25 data from the HURON trial at 8, 16 and 26 weeks, adjusted by the baseline VFQ-
25, to predict EQ-5D at these time points using the linear regression.  
Permanent blindness 
A goal of the use of the dexamethasone implant is to prevent permanent damage to the eye. It was 
therefore important to include a rate of blindness and the impact of dexamethasone upon that rate. 
However, this outcome was not captured by the HURON trial due to its short duration.[4] Given the 
lack of evidence, only blindness in both eyes was incorporated into the model. A study by Dick et 
al.[11] was used to estimate the rate of blindness for people with uveitis receiving current care. This 
was a retrospective analysis of insurance claims data (n=1769) where all patients had posterior 
segment, non-infectious uveitis, and provided an estimate of 6.6% of patients going blind within 10 
years. Two other sources were also identified and were used in sensitivity analyses; Tomkins-Netzer 
et al.,[20] which included a wider population than our target population (including patients with 
infectious and anterior uveitis) and, Durrani et al.,[21] based on a tertiary referral centre. It was 
assumed that the dexamethasone implant could halve the number of cases of blindness over the 6 
months that it is effective. Since there is no evidence about this parameter, it was varied within 
sensitivity analyses.   
7KHXWLOLW\DVVRFLDWHGZLWKWKH³EOLQGQHVV´KHDOWKVWDWHZDVWDNHQIURPDVWXG\E\&]RVNL-Murray et 
al.[10] who used contact lenses to simulate blindness associated with age-related macular 
degeneration. 
Adverse events 
Given that quality of life data were used directly to model treatment effectiveness, it was assumed that 
the impact on quality of life associated with adverse events (AEs) whilst on treatment would be 
already captured. Therefore, only the additional costs associated with the management of AEs were 
modelled and the AEs included within the model are limited to those where the cost of treatment is 
substantial: cataract, raised intraocular pressure, glaucoma, serious infections; hypertension; fractures; 
and diabetes. The probabilities for AEs per cycle were calculated based on the incidence and mean 
follow-up in the HURON trial. 
Costs 
The model includes treatment costs, administration costs and monitoring costs, as well as adverse 
event costs and the cost of permanent blindness, as shown in Table 1. The model assumes that all 
patients would receive monitoring every 6 weeks, irrespective of treatment, consisting of outpatient 
visits to assess the efficacy of the treatments and to monitor the risk of AEs. It is assumed that patients 
receiving immunosuppressants would have 6 additional blood monitoring visits annually.  
Model analysis 
Probabilistic sensitivity analyses (PSA) were run using Monte Carlo simulation with 5,000 samples. 
This allows for non-linearity in the model and incorporates distributions around each model input 
parameter to capture the uncertainty around their true value, leading to an estimate of the uncertainty 
in the model results. Deterministic results have also been produced which simply use the best estimate 
for each parameter in the model. Due to the scarcity of appropriate evidence on key model 
parameters, a range of exploratory analyses were undertaken in order to assess the impact of 
alternative assumptions upon the model results. Where deterministic and probabilistic central results 
are similar, the deterministic model can be used within exploratory analyses to reduce model run time. 
For more details on the model, please refer to the corresponding HTA report.[3] 
RESULTS 
The key model results are presented in Table 222 and Table 3. A single dexamethasone implant 
combined with limited current practice as provided in the HURON trial (DEX + LCP(H)) was 
estimated to result in a probabilistic ICER of £19,509 per QALY gained compared with LCP (H). 
However, there is substantial uncertainty around this result. Based on the uncertainty around the 
model parameters, there is an estimated 72% chance that the dexamethasone implant will be a good 
use of resources if the decision maker is willing to pay £30,000 for each QALY gained.  
Given the paucity of evidence, a number of alternative assumptions have been tested within 
exploratory analyses to assess their impact upon the model results. The first exploratory analysis 
considers a comparator which is more representative of current UK practice than the comparator arm 
of HURON. The comparator arm of the MUST trial[5] (identified within the systematic review), is 
made up of patients who received systemic corticosteroids, supplemented in 86% of the cases with 
immunosuppressants and is thought to be reasonably representative of UK clinical practice. Data from 
this trial was used for: (a) an estimate of the total proportion of patients receiving (i) corticosteroids 
and (ii) immunosuppressants in order to estimate costs; (b) an estimate of the HRQoL of patients, and; 
(c) the rates for any adverse events associated with substantial resource use. It is assumed within this 
exploratory analysis that patients treated with dexamethasone are also able to receive 
immunosuppressants and corticosteroids. This analysis results in both arms being associated with 
greater costs and greater QALYs, whilst the incremental ICER remains similar (see Table 2).    
Whilst the observational studies undertaken to date suggest that the treatment effect of dexamethasone 
is around 6 months, there is some uncertainty around this, with some studies suggesting time to 
treatment failure may be longer. As such, the second exploratory analysis varies the length of the 
treatment effect of the dexamethasone implant (see Table 2) from 26 weeks to 42 weeks. The ICER 
for DEX + LCP(H) versus LCP(H) varies from £12,154 to £24,715 per QALY gained. 
Table 22:  Model results  
 
Total 
QALYs 
Total 
costs 
Inc. 
QALYs 
Inc. 
costs ICER 
Probability of cost-
effectiveness at WTP 
threshold 
£20,000 £30,000 
Main results (probabilistic) 
LCP(H)* 14.599 £39,992       0.53 0.28 
DEX + LCP(H)* 14.629 £40,565 0.029 £573 £19,509 0.47 0.72 
Main results (deterministic) 
LCP(H)* 14.613 £39,655       N/A N/A 
DEX + LCP(H)* 14.641 £40,235 0.029 £580 £20,058 N/A N/A 
Exploratory analysis 1: comparing dexamethasone with arm from the MUST trial 
(probabilistic) 
CP(M)** 15.152 £63,465       0.54 0.45 
DEX + LCP(H)* 
before CP(M)** 15.163 £63,681 0.011 £216 £19,899 0.47 0.55 
Exploratory analysis 2: varying duration of treatment effect (deterministic) 
LCP(H)  14.613 £39,655       N/A N/A 
Dex:26 weeks 14.637 £40,256 0.024 £600 £24,715 N/A N/A 
Dex:30 weeks* 14.641 £40,235 0.029 £580 £20,058 N/A N/A 
Dex:34 weeks 14.646 £40,214 0.033 £559 £16,692 N/A N/A 
Dex:42 weeks 14.655 £40,173 0.043 £518 £12,154 N/A N/A 
*LCP(H)= Limited current practice, as provided in the HURON trial:25% of patients on anti-inflammatory or 
immunosuppressant medication. 
**CP(M)= Current practice as provided in the MUST trial: all patients on systemic steroids and 86% on 
systemic immunosuppressants. 
 
 
The third exploratory analysis varies the rate of blindness for patients receiving current care at the 
same time as varying the relative risk of blindness when receiving dexamethasone.  Table 3 shows the 
resulting incremental cost per QALYs gained. These results show that the impact of dexamethasone 
upon blindness is a key model parameter and as such model results can range from dexamethasone 
being cost saving to having a cost per QALY above the currently accepted thresholds for cost-
effectiveness within England. For example, if the current rate of blindness is taken from the study by 
Durrani et al.[21] and dexamethasone has no effect on the rate of permanent blindness then the 
dexamethasone implant is estimated to have a cost per QALY gained of £56,329 compared with 
current practice. Longer term research is needed to reduce the uncertainty around this parameter and 
hence around the model results. 
Table 3: ICERs when varying rate of blindness and relative risk of blindness on dexamethasone 
Source 
Rate of 
blindness 
(annual) 
RR of blindness whilst on dexamethasone 
0 (no 
blindness) 0.25  0.50* 0.75 
1 (no 
effect) 
Assumption 0 £48,937 £48,937 £48,937 £48,937 £48,937 
Tomkins-Netzer et 
al.[20]  
0.0038 
£17,100 £21,816 £28,089 £36,844 £49,915 
Dick et al.[11]* 0.0066 £8,688 £13,314 £20,058* £30,805 £50,627 
Durrani et al.[21] 0.0374 Dominates Dominates £557 £10,900 £56,329 
*main result 
µ'RPLQDWHV¶PHDQVWKDWWKHGH[DPHWKDVRQHLVHVWLPDWHGWREHPRUHHIIHFWLYHDQGOHVVFRVWO\WKDQFXUUHQWFDUH 
 
The HURON trial did not provide outcomes separately for patients with bilateral and unilateral 
disease; however these exploratory results suggest that the dexamethasone implant may not be 
considered to be cost-effective, using standard thresholds of cost-effectiveness in England, in patients 
with unilateral disease since it will not prevent blindness in these patients. However, patients may 
later go on to develop uveitis in the second eye, and hence by preserving vision in the first eye the 
implant may prevent future blindness, thus improving cost-effectiveness in this group. 
In addition to the above analysis, each of the key model parameters was modified individually within 
plausible ranges to test their impact upon the model results. The only other parameter which impacted 
the ICER by more than £2,000 was the utility associated with blindness. This utility was changed 
from 0.38 (Czoski-Murray et al.[10]) to 0.57 (Brown et al.[22]) which resulted in a deterministic 
ICER of £25,257 per QALY gained for dexamethasone plus LCP(H) compared with LCP(H).  
DISCUSSION 
The HURON study presented outcomes at 26 weeks and no patients went blind within the trial period, 
making the model predictions about the proportion of patients going blind over the long term highly 
uncertain. Research around how short-term improvements in visual acuity or inflammation relate to 
long-term effects on moderate to severe vision loss and blindness would provide more robust 
estimates of the cost-effectiveness of dexamethasone. 
The model assumes that only one dexamethasone implant would be provided to patients. There are 
several non-randomised studies with 12±24 months follow up, which allow repeat implants.[23-25] 
7KHVHVWXGLHVVXJJHVWWKDWDIWHUDURXQGVL[PRQWKVSDWLHQWV¶RXWFRPHVUHWXUQWRWKRVHDWEDVHOLQHDQG
second and third implants are associated with effects similar to first implants. Each additional implant 
is associated with a higher incidence of adverse events such as intraocular pressure (IOP) and 
cataract,[23-25] and this would limit repeated use. The univariate sensitivity analyses suggested that 
the model is not sensitive to the cost of IOP or cataract, and hence, given that the cost of each implant 
is the same, the cost-effectiveness of up to three consecutive implants is expected to be similar to the 
cost-effectiveness of one implant. The ICER would be expected to decrease if there was also a 
cumulative impact upon the reduction in blindness or if patients were to achieve remission after 
consecutive implants.  
There is insufficient evidence to assess the cost-effectiveness of using dexamethasone implants in 
both eyes for a patient with bilateral disease. However, because the costs would essentially be doubled 
(with the exception of some monitoring costs) and the increment in HRQoL is likely to be lower for 
the second eye, it is expected to be less cost-effective than treatment in one eye.  
This analysis takes a NHS and PSS perspective as required by NICE and does not include broader 
societal impacts such as productivity loss. NICE produced guidance,[7] informed by this analysis, that 
dexamethasone is recommended in the NHS as an option for treating non-infectious uveitis in the 
posterior segment of the eye in adults with active disease and worsening vision with a risk of 
blindness. However, considerable uncertainty remains due to lack of evidence on the long-term 
treatment effect (such as avoiding permanent blindness and visual impairment), on the prevalence of 
permanent blindness and visual impairment in the target population and on utility values after the 
onset of blindness. There is a serious unmet need to gather more primary data in this area to support 
health economic decisions in uveitis without which inappropriate resource allocation decisions are 
more likely to be made.  
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FIGURE LEGENDS 
Figure 1: State transition diagram of the decision model 
Figure 2: The relationship between VFQ-25 and EQ-5D based on patient-level data from the HURON 
trial 
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